These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 37856201)
21. Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients. Lattimore V; Parsons MT; Spurdle AB; Pearson J; Lehnert K; Sullivan J; Lintott C; Bawden S; Morrin H; Robinson B; Walker L Breast Cancer Res Treat; 2021 Feb; 185(3):583-590. PubMed ID: 33113089 [TBL] [Abstract][Full Text] [Related]
22. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil. Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148 [TBL] [Abstract][Full Text] [Related]
23. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers. Cragun D; Weidner A; Tezak A; Clouse K; Pal T Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176 [TBL] [Abstract][Full Text] [Related]
24. [Prophylactic surgery of mammary and ovarian carcinoma]. Lux MP; Bani MR; Fasching PA; Beckmann MW Chirurg; 2005 Dec; 76(12):1145-54. PubMed ID: 16237564 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of Clinical Guidelines in Identifying All Japanese Patients with Hereditary Breast and Ovarian Cancer. Haneda E; Sato A; Suganuma N; Sebata Y; Okamoto S; Toda S; Kohagura K; Matsubara Y; Sugawara Y; Yamanaka T; Yamashita T; Shimizu S; Narimatsu H Int J Environ Res Public Health; 2022 May; 19(10):. PubMed ID: 35627717 [TBL] [Abstract][Full Text] [Related]
26. Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients. Rodríguez-Balada M; Roig B; Melé M; Albacar C; Serrano S; Salvat M; Querol M; Borràs J; Martorell L; Gumà J Clin Biochem; 2020 Feb; 76():17-23. PubMed ID: 31786208 [TBL] [Abstract][Full Text] [Related]
27. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer. Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968 [TBL] [Abstract][Full Text] [Related]
29. The genetics of hereditary cancer risk syndromes in Brazil: a comprehensive analysis of 1682 patients. de Oliveira JM; Zurro NB; Coelho AVC; Caraciolo MP; de Alexandre RB; Cervato MC; Minillo RM; de Vasconcelos Carvalho Neto G; Grivicich I; Oliveira JB Eur J Hum Genet; 2022 Jul; 30(7):818-823. PubMed ID: 35534704 [TBL] [Abstract][Full Text] [Related]
30. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Fortuno C; James PA; Spurdle AB Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537 [TBL] [Abstract][Full Text] [Related]
31. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective. Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682 [TBL] [Abstract][Full Text] [Related]
32. Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication. Pelttari LM; Shimelis H; Toiminen H; Kvist A; Törngren T; Borg Å; Blomqvist C; Bützow R; Couch F; Aittomäki K; Nevanlinna H Clin Genet; 2018 Mar; 93(3):595-602. PubMed ID: 28802053 [TBL] [Abstract][Full Text] [Related]
33. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations. Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230 [TBL] [Abstract][Full Text] [Related]
34. The Clinical Utility of Next Generation Sequencing Results in a Community-Based Hereditary Cancer Risk Program. Bunnell AE; Garby CA; Pearson EJ; Walker SA; Panos LE; Blum JL J Genet Couns; 2017 Feb; 26(1):105-112. PubMed ID: 27276934 [TBL] [Abstract][Full Text] [Related]
35. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland. McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389 [TBL] [Abstract][Full Text] [Related]
36. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population. Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661 [TBL] [Abstract][Full Text] [Related]
37. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families. Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231 [TBL] [Abstract][Full Text] [Related]
38. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment. Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727 [TBL] [Abstract][Full Text] [Related]
39. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds. Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920 [TBL] [Abstract][Full Text] [Related]